

Opportunity Title: FDA Negative Pediatric Clinical Trials Fellowship **Opportunity Reference Code:** FDA-CDER-2024-1444

Organization U.S. Food and Drug Administration (FDA)

Reference Code FDA-CDER-2024-1444

How to Apply To submit your application, scroll to the bottom of this opportunity and click APPLY.

A complete application consists of:

- · An application
- Transcripts <u>Click here for detailed information about acceptable</u> <u>transcripts</u>
- A current resume/CV, including academic history, employment history, relevant experiences, and publication list
- · One educational or professional recommendation

All documents must be in English or include an official English translation.

If you have questions, send an email to <u>ORISE.FDA.CDER@orau.org</u>. Please include the reference code for this opportunity in your email.

Connect with ORISE...on the GO! Download the new ORISE GO mobile app in the <u>Apple App Store</u> or <u>Google Play Store</u> to help you stay engaged, connected, and informed during your ORISE experience and beyond!

Application Deadline 8/30/2024 3:00:00 PM Eastern Time Zone

Description *Applications will be reviewed on a rolling-basis.

FDA Office and Location: A research opportunity is available in the Office of New Drugs/ Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine (ORPURM), Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA) located at the Office of Regulatory Affairs (ORA) Pacific Southwest Medical Products Laboratory in Silver Spring, Maryland.

The Center for Drug Evaluation and Research (CDER) performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the U.S. Food and Drug Administration (FDA), CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. This work covers more than just medicines.

Research Project: Up to 42% of recently completed pediatric trials have failed to establish either safety or efficacy, with the majority failing to establish efficacy, leading to an inability to label the product for use in children. ORPURM is proposing a retrospective review and analysis of patient level data (adult and pediatric) from former new drug applications (NDAs) to explore trial design elements or conduct that may contribute to the negative findings and provide a framework for optimizing trial design for future pediatric drug development.

Learning Objectives: Under the guidance of a mentor, the participant will gain knowledge in trial design considerations that can impact response in drug development. In addition, the participant will learn about methodological features of studies, data curation and database building, data analysis, and dissemination of results (presentations, publications).



W ORISE GO



The ORISE GO mobile app helps you stay engaged, connected and informed during your ORISE experience – from application, to offer, through your appointment and even as an ORISE alum!





Opportunity Title: FDA Negative Pediatric Clinical Trials Fellowship Opportunity Reference Code: FDA-CDER-2024-1444

Anticipated Appointment Start Date: 2024. Start date is flexible and will depend on a variety of factors.

Appointment Length: The appointment will initially be for one year, but may be renewed upon recommendation of FDA and is contingent on the availability of funds.

Level of Participation: The appointment is full time.

Citizenship Requirements: This opportunity is available to U.S. citizens, Lawful Permanent Residents (LPR), and foreign nationals. Non-U.S. citizen applicants should refer to the <u>Guidelines for Non-U.S. Citizens</u> <u>Details page</u> of the program website for information about the valid immigration statuses that are acceptable for program participation.

This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.

Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.

FDA Ethics Requirements

If an ORISE Fellow, to include their spouse and minor children, reports what is identified as a Significantly Regulated Organization (SRO) or prohibited investment fund financial interest in any amount, or a relationship with an SRO, except for spousal employment with an SRO, and the individual will not voluntarily divest the financial interest or terminate the relationship, then the individual is not placed at FDA. For additional requirements, see <u>FDA Ethics for Nonemployee Scientists</u>.

FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:

- Non-employee nature of the ORISE appointment;
- Prohibition on ORISE Fellows performing inherently governmental functions;
- Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship;
- · The fact that research materials and laboratory notebooks are the



Opportunity Title: FDA Negative Pediatric Clinical Trials Fellowship **Opportunity Reference Code:** FDA-CDER-2024-1444

property of the FDA;
ORISE fellow's obligation to protect and not to further disclose or use non-public information.
Qualifications
The qualified candidate should have received or be currently pursuing a bachelor's, master's or doctoral degree in one of the relevant fields. Degree must have been received within five years of the appointment start date.
Eligibility

 Degree: Bachelor's Degree, Master's Degree, or Doctoral Degree received within the last 60 months or currently pursuing.
 Discipline(s):

 Life Health and Medical Sciences (51.
 Life Health and Medical Sciences (51.
 and
 Mathematical Sciences (51.
 Second months. (36 months do not have to be consecutive.)
 and

 Descret the second months is the second months or the past 60 months.
 Second months is the second months in the second months is the second months in the second months is the second months.
 Second months is the second months in the second months is the second months.
 Second months is the second months in the second months in the second months is the second months.
 Second months is the second months in the second months is the second months in the second months is the second month in the second month is the second month is the secon

I have read the FDA Ethics Requirements.